ContraFect‘s patent provides methods for treating influenza viruses with intranasal or inhalation administration of neutralizing antibodies. The composition includes IgG monoclonal antibodies effective against influenza A and B viruses, with specific combinations for treatment or prophylaxis. The patent aims to provide effective intranasal treatment options for influenza infections. GlobalData’s report on ContraFect gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ContraFect, Glycoside hydrolase-based drug compositions was a key innovation area identified from patents. ContraFect's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Intranasal or inhalation administration of antibodies for influenza treatment
See Also:
A recently granted patent (Publication Number: US11827693B2) discloses a composition designed for intranasal or inhalation administration to treat or prevent influenza viral infections in mammals. The composition includes specific combinations of monoclonal IgG antibodies or antigen-binding fragments capable of neutralizing influenza A H1, influenza A H3, and influenza B viruses from the Yamagata and Victoria lineages. The antibodies are formulated with a pharmaceutically acceptable excipient, carrier, or diluent, with single unit doses of each antibody present in amounts effective for influenza treatment or prophylaxis. The patent also covers methods for inhibiting influenza virus transmission by administering the composition within specific timeframes after exposure or symptom onset, with doses ranging from less than 0.5 mg/kg to 1 mg/kg.
Furthermore, the patent details the specific combinations of antibodies, unit doses, and administration protocols for optimal efficacy in treating or preventing influenza infections. The composition may also include additives for nasal or pulmonary delivery and immunological mediators to enhance the immune response. The patent emphasizes the importance of timely administration of the monoclonal IgG antibodies to inhibit virus transmission effectively. Additionally, the patent specifies the antibody effector functions and antibody fragments used in the composition, highlighting the precise formulation required for maximum therapeutic benefit. Overall, the patent provides a comprehensive framework for utilizing monoclonal IgG antibodies in combating influenza infections, offering a promising avenue for improved treatment and prevention strategies in the future.
To know more about GlobalData’s detailed insights on ContraFect, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
